Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 294

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 294
---
   |              |   |     |        |          |   |
| Interest expense                   |     |                     |       59,540 |   |     |   |       33,473 |   |     |        |   26,067 |   |
| Total other expense                |     |                     |       59,541 |   |     |   |       33,473 |   |     |        |   26,068 |   |
| Net loss before income taxes       |     |                     |     (479,364 | ) |     |   |     (373,090 | ) |     |        |  106,274 |   |
| Income taxes                       |     |                     |       14,346 |   |     |   |       82,383 |   |     |        |  (68,037 | ) |
| Net loss                           |     | $                   |     (493,710 | ) |     | $ |     (455,673 | ) |     | $      |   38,037 |   |

Revenue Grant revenue was $531,729 for the nine months ended February 28, 2025 compared to $990,443 for the nine months ended February 29, 2024. The decrease was due to lower reimbursable direct labor, consulting and other development expenses for DiamiR’s CogniMIR ®product candidate and, subsequently, the depletion of available grant funding in January 2025. As of February 28, 2025, DiamiR has no remaining funds under its grants. As of February 28, 2025, DiamiR has received and applied all available funding under its grants and grant revenues will decrease significantly or cease in future periods. Other revenue in the nine months ended February 28, 2025 consists of nonrecurring fees from a non -customerunder a material transfer agreement. Research and Development Expenses DiamiR expenses the cost of research and development as incurred. Research and development expenses comprise costs incurred in performing research and development activities, including clinical study costs, contracted services, personnel costs, including stock -basedcompensation, and other external costs. Personnel costs include the majority of compensation paid to DiamiR’s CEO, representing his participation in research and development activities. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity is performed or when the goods have been received, rather than